NasdaqHealth CareHealth Care ServicesS&P MidCap 400
$16.01
+0.14 (+0.88%)
Close of Nov 06, 2026 · end-of-day data
SHC 8-K filings in 2025
Every material Form 8-K Sotera Health filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Sotera Health reported third-quarter 2025 net revenues up 9.1% to $311 million and net income of $48 million, or $0.17 per diluted share, compared with $17 million, or $0.06, a year earlier. The company raised its 2025 Adjusted EBITDA growth outlook to 6.75% to 7.75% and kept its net revenue growth outlook at 4.5% to 6.0%, on a constant currency basis.
Q3 2025 net income was $48 million, or $0.17 per diluted share, versus $17 million, or $0.06, in Q3 2024.
Q3 2025 Adjusted EBITDA rose 12.2% to $164 million; Adjusted EPS was $0.26, up from $0.17.
2025 Adjusted EBITDA growth outlook raised to 6.75% to 7.75%, from 6.00% to 7.50%.
2025 Adjusted EPS outlook raised to $0.81 to $0.86, from $0.75 to $0.82; net revenue outlook reaffirmed at 4.5% to 6.0%.
Sotera Health entered Amendment No. 6 to its First Lien Credit Agreement on September 17, 2025, which reprices its term loans. The Repriced Term Loans total $1,423,029,875 after the company used $75,000,000 of available cash to repay part of its term loan facility, and they mature on May 30, 2031. The amendment lowers the interest rate spread by 0.50%, which matters to shareholders because it reduces the company's borrowing cost on this debt.
Repriced Term Loans total $1,423,029,875 to Sotera Health Holdings, LLC, after a $75,000,000 cash repayment
Interest margin set at Adjusted Term SOFR plus 2.50%, reflecting a 0.50% reduction from this amendment and a previously triggered 0.25% step-down
Loans amortize at 1.00% per year, mature May 30, 2031, and carry a 1.00% soft call premium for repricings within six months
Amendment filed as Exhibit 10.1; JPMorgan Chase Bank, N.A. is first lien Administrative Agent
Sotera Health reported second-quarter 2025 net revenues up 6.4% to $294 million and Adjusted EBITDA up 9.8% to $151 million, and raised its full-year 2025 outlook for revenue, Adjusted EBITDA and Adjusted EPS. GAAP net income was $8 million, or $0.03 per diluted share, slightly below $9 million a year earlier, and includes a pending settlement of about $34 million related to ethylene oxide claims against Sterigenics.
Q2 2025 net revenues rose 6.4% to $294 million; Adjusted EBITDA rose 9.8% to $151 million
Q2 2025 net income was $8 million, or $0.03 per diluted share, versus $9 million, or $0.03, in Q2 2024
Full-year 2025 Adjusted EPS outlook raised to $0.75 to $0.82 from $0.70 to $0.76
Six-month net loss of $5 million, or $0.02 per diluted share, includes settlements related to ethylene oxide claims
Sotera Health reported first-quarter 2025 net revenues up 2.6% to $255 million and Adjusted EBITDA up 8.8% to $122 million, but a net loss of $13 million, or $0.05 per diluted share, after an approximately $31 million EO claims settlement against Sterigenics. The company reaffirmed its full-year 2025 outlook for net revenue growth of 4.0% to 6.0% and Adjusted EBITDA growth of 4.5% to 6.5%, on a constant currency basis.
Net revenues rose 2.6% to $255 million (4.4% on a constant currency basis) versus Q1 2024.
Net loss of $13 million, or $0.05 per diluted share, compared with net income of $6 million, or $0.02, in Q1 2024; includes an approximately $31 million Illinois EO litigation settlement.
Adjusted EBITDA rose 8.8% to $122 million; Adjusted EPS was $0.14, up $0.01 from $0.13.
2025 outlook reaffirmed: net revenue growth of 4.0% to 6.0% and Adjusted EBITDA growth of 4.5% to 6.5%, constant currency; Adjusted EPS of $0.70 to $0.76.
Sotera Health reported fourth-quarter and full-year 2024 results and issued its initial 2025 outlook. Full-year net revenues rose 4.9% to $1.10 billion, but net income fell from $51 million to $44 million and Adjusted EPS declined $0.02 to $0.70. The company expects 2025 net revenue growth of 4.0% to 6.0% and Adjusted EPS of $0.70 to $0.76.
Fourth-quarter 2024 net revenues fell 6.5% to $290 million; net income was $12 million, or $0.04 per diluted share, versus $39 million a year earlier.
Full-year 2024 diluted EPS was $0.16 versus $0.18 in 2023; Adjusted EPS was $0.70.
2025 outlook: net revenue growth of 4.0% to 6.0% and Adjusted EPS of $0.70 to $0.76, with net revenue growth on a constant currency basis.
Nordion fourth-quarter net revenues fell 28.9% to $57 million, which the company attributed to the timing of cobalt harvest schedules.
Sotera Health said preliminary full-year 2024 revenue is approximately $1.1 billion, growth of nearly 5% over 2023 and more than 5% on a constant currency basis. The company said the figure is within the revenue guidance it gave with its third-quarter 2024 results, but it remains subject to year-end closing procedures and audit, so final results may differ materially.
Preliminary full-year 2024 revenue of approximately $1.1 billion, up nearly 5% versus 2023 and more than 5% on a constant currency basis
Revenue range is within the guidance given at the third-quarter 2024 earnings release
Chairman and CEO Michael B. Petras, Jr. presents a business update at the J.P. Morgan Healthcare Conference on January 14, 2025 at 11:15 a.m. Eastern Time
Full 2024 results and 2025 outlook are scheduled for release on February 27, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Sotera Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →